Logo
RRS HA Long Lasting 1x3ml

RRS HA Long Lasting 1x3ml

RRS

Injectable Aesthetic Treatment
  • Sterile Class III medical device.
  • CE Marked in conformity with Directive 93/42/EEC for medical devices.
  • Manufactured using biotechnological, non Animal origin hyaluronic acid.
  • Produced under quality and safety standards applicable to injectable medical devices in the EU.
Biorevitalising Dermal Implant / Mesohybrid Skin Booster

Description

RRS HA Long Lasting 1x3ml is an advanced biorevitalising dermal implant combining highly concentrated, BDDE cross-linked hyaluronic acid with an amino acid antioxidant buffer. Classified as a sterile Class III CE-marked medical device, it is designed for injection by trained physicians to treat skin photoageing, dermal atrophy and loss of elasticity. The formulation provides deep, long-lasting hydration, improves skin density and elasticity, soft-fills fine lines and wrinkles, and enhances overall skin quality. Hyaluronic acid of non-animal, biotechnological origin is solubilized in a protective amino acid buffer that stabilizes the HA, slows biodegradation and reduces osmotic stress, resulting in a longer-lasting, skin-building effect compared to traditional mesotherapy cocktails.

Bnefits

  • Provides deep and long-lasting skin hydration.
  • Improves skin elasticity, firmness and turgor.
  • Soft-fills fine lines and moderate wrinkles without an over-filled look.
  • Redensifies dermal tissue and helps treat dermal atrophy.
  • Improves overall skin quality, texture, tone and radiance.
  • Helps counteract signs of photoageing such as roughness, elastosis and dullness.
  • Hybrid behaviour, combining properties of a dermal filler and a skin booster (mesohybrid).
  • Amino acid buffer stabilizes hyaluronic acid, slows biodegradation and offers antioxidant protection.
  • Cross-linked, non-animal hyaluronic acid for improved longevity and good tolerability.
  • Suitable for 3D skin rejuvenation of face, neck, décolleté and hands.
  • CE-marked Class III medical device manufactured under European medical device regulations.

Indications

  • Treatment of skin photoageing and its consequences (fine lines, roughness, loss of radiance).
  • Treatment of dermal atrophy and devitalised, thin skin.
  • Long-lasting hydration and improvement of skin elasticity and tone.
  • Reduction of fine lines and moderate wrinkles.
  • Soft lifting and redensification of lax, sagging skin.
  • Biorevitalisation and improvement of overall skin quality (texture, glow, firmness).
  • Supportive treatment for sun-damaged, dehydrated or mature skin.
  • 3D rejuvenation of face, neck, décolleté and hands.

Composition

  • BDDE cross-linked hyaluronic acid 21 mg / 3 ml (biotechnological, non-animal origin).
  • Amino acid protective buffer 14.52 mg / 3 ml (mixture of approximately 15 amino acids with hydrating and antioxidant properties).

Formulation

  • Sterile, pyrogen-free, Class III CE-marked dermal implant.
  • Pre-filled syringe containing 3 ml of BDDE cross-linked hyaluronic acid (21 mg/3 ml) in an amino acid buffer (14.52 mg/3 ml).
  • Non-animal origin hyaluronic acid with high molecular weight, stabilized for prolonged residence time.
  • Hybrid dermal filler/skin booster (mesohybrid) concept with gradual, metered HA release.
  • Lidocaine-free formulation.

Packaging

  • Box containing 1 pre-filled syringe x 3 ml of RRS HA Long Lasting.
  • Single-use sterile syringe presentation.
  • Supplied with traceability labels and professional instructions for use.
  • CE Class III medical device labelling in conformity with Directive 93/42/EEC.

Usage

  • For professional use only: must be injected exclusively by a legally authorised physician or suitably qualified medical professional in a regulated clinical setting.
  • Inspect packaging and syringe integrity before use; do not use if the sterile blister or syringe is damaged or if the expiry date has passed.
  • Clean and disinfect the treatment area thoroughly according to local aseptic protocols.
  • Inject intradermally or in the superficial to mid-dermis using an appropriate needle (commonly 27–30G) following the manufacturer’s protocol (e.g. 7-point technique on each half of the face).
  • Typical treatment course: series of 2–3 sessions spaced approximately 3–4 weeks apart, according to clinical evaluation and product guidelines.
  • Gently massage the treated area after injection to ensure even distribution of the product.
  • Plan maintenance sessions approximately every 6–9 months or as dictated by the patient’s skin condition and practitioner assessment.
  • Do not inject into blood vessels, mucosae, inflamed or infected skin or in areas previously treated with permanent fillers.
  • Inform patients about possible transient side effects such as redness, swelling or bruising and provide written aftercare instructions (e.g. avoiding heat, saunas, strenuous exercise, and makeup for 24 hours; sun protection).
  • Dispose of used syringes and needles as clinical sharps waste in accordance with local regulations.

Contraindications

  • Hypersensitivity or known allergy to hyaluronic acid, amino acids, BDDE or any component of the formulation.
  • Presence of active skin infections, inflammation, herpes lesions or dermatological diseases at or near the injection site.
  • History of severe allergic reactions or anaphylaxis to injectable products.
  • Known tendency to hypertrophic scars or keloid formation in the intended treatment area.
  • Autoimmune diseases or immunosuppression, unless the physician has carefully evaluated the risk–benefit profile.
  • Pregnancy and breastfeeding (use is generally contraindicated for elective aesthetic procedures).
  • Previous permanent fillers or implants in the planned injection area, unless managed by an experienced injector under strict indication.
  • Intravascular injection, injection into the eyelids, or into areas where vascular compromise risk is high, must be strictly avoided.

Adverse Effects

  • Common transient reactions at injection sites: redness, swelling, tenderness, pain, itching, bruising or mild induration.
  • Temporary lumps or nodules at injection points, usually resolving with massage or spontaneously.
  • Rare but more significant events: infection, abscess, persistent nodules or granulomatous reactions.
  • Very rare but serious complications if inadvertently injected intravascularly, including vascular occlusion, skin necrosis, or visual disturbances; these require immediate emergency management.
  • Hypersensitivity or allergic reactions to product components, which may manifest as prolonged swelling, erythema or induration.

Storage Conditions

  • Store at a controlled room temperature according to manufacturer recommendations (typically between 2°C and 25°C).
  • Protect from extremes of heat and cold; do not freeze.
  • Keep the syringe in its original blister and carton until use to maintain sterility and protect from light.
  • Do not use after the expiry date printed on the packaging.
  • Keep out of the reach of children.

Duration

Effects are designed to be long-lasting; a typical protocol involves 2\u20133 initial sessions spaced 3\u20134 weeks apart with maintenance treatments approximately every 6\u20139 months, depending on individual skin condition and practitioner assessment.

Onset

Hydration and plumping effects are often visible immediately after injection, with progressive improvement in skin quality, elasticity and fine lines over the following weeks as the product integrates and tissue regenerates.

Browse more Injectable Aesthetic Treatment

Top Treatments

Top Cities in the UK